Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)

Key Inclusion Criteria:

   - Up to 5 prior regimens for MCL. Prior therapy must have included anthracycline- or
   bendamustine-containing chemotherapy and anti-CD20 monoclonal antibody therapy.
   Individuals must not have received prior therapy with a BTKi.

   - At least 1 measurable lesion

   - Platelet count ≥ 75,000/uL

   - Creatinine clearance (as estimated by Cockcroft Gault) ≥ to 60 cc/min

   - Cardiac ejection fraction ≥ 50%, no evidence of pericardial effusion as determined by
   an echocardiogram (ECHO) or multigated acquisition (MUGA), and no clinically
   significant electrocardiogram (ECG) findings

   - Baseline oxygen saturation > 92% on room air

Key Exclusion Criteria:

   - Known history of infection with human immunodeficiency virus (HIV) or hepatitis B
   (HBsAG positive) or hepatitis C virus (anti-HCV positive). Individuals with a history
   of hepatitis infection must have cleared their infection as determined by standard
   serological and genetic testing

   - History of a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia,
   cerebellar disease, cerebral edema, posterior reversible encephalopathy syndrome, or
   any autoimmune disease with central nervous system (CNS) involvement

   - Presence of fungal, bacterial, viral, or other infection that is uncontrolled or
   requiring IV antimicrobials for management

Note: Other protocol defined Inclusion/Exclusion criteria may apply.